GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » EPS without NRI

Prostatype Genomics AB (OSTO:PROGEN) EPS without NRI : kr-0.28 (TTM As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB EPS without NRI?

Prostatype Genomics AB's earnings per share without non-recurring items for the three months ended in Jun. 2023 was kr-0.05. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was kr-0.28.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Prostatype Genomics AB's EPS without NRI or its related term are showing as below:

OSTO:PROGEN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -80.8   Med: -50.95   Max: -21.1
Current: -21.1

OSTO:PROGEN's 3-Year EPS without NRI Growth Rate is ranked worse than
75.29% of 170 companies
in the Medical Diagnostics & Research industry
Industry Median: -0.35 vs OSTO:PROGEN: -21.10

Prostatype Genomics AB's EPS (Diluted) for the three months ended in Jun. 2023 was kr-0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was kr-0.28.

Prostatype Genomics AB's EPS (Basic) for the three months ended in Jun. 2023 was kr-0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was kr-0.28.


Prostatype Genomics AB EPS without NRI Historical Data

The historical data trend for Prostatype Genomics AB's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB EPS without NRI Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23
EPS without NRI
-0.22 -0.20 -0.22 -1.27 -0.35

Prostatype Genomics AB Quarterly Data
Jun18 Jun19 Mar20 Jun20 Sep20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.08 -0.07 -0.05 -

Competitive Comparison of Prostatype Genomics AB's EPS without NRI

For the Diagnostics & Research subindustry, Prostatype Genomics AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prostatype Genomics AB's PE Ratio without NRI Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's PE Ratio without NRI falls into.



Prostatype Genomics AB EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prostatype Genomics AB  (OSTO:PROGEN) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Prostatype Genomics AB EPS without NRI Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Prostatype Genomics AB (OSTO:PROGEN) Business Description

Traded in Other Exchanges
Address
Gustaf III:s Boulevard 34, Solna, SWE, 169 73
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines